FOXO3 and chronic obstructive pulmonary disease: Furthermore, increasing concentrations of CSE (5%, 10% and 20%) promoted a dose‐dependent reduction in FoxO3 in PBECs from control subjects (Fig. 1B), but not in COPD‐derived PBECs.